Rejected at 11:44 p.m. Oct, 31, 2023 ] by dollajas
Author: ZigWiggy
Related Note: 1503254160003 1
Rationale for change

otherwise you think it's asking for a cell (macrophages)

Rejection reason

this is actually quite HY - knowing it cold with no hint may be beneficial

Text Text
Extra
- Individuals who are to be started on a TNF-α inhibitor (e.g., infliximab) should receive a PPD test

- Lack of TNF-α = lack of granuloma = lack of containment of tuberculosis


Photo credit: Ed Uthman, MDCC BY-SA 2.0, via Wikimedia Commons; the supplementary image with overlays of the relevant areas was adapted from the image mentioned previously, licensed under CC BY-SA 2.0
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid



Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Physeo




OME

Additional Resources
One by one
Empty field
#AK_Step2_v12::#AMBOSS::dnaoHO #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::10_TNF-alpha_inhibitors::*Basics #AK_Step1_v12::#AMBOSS::tWaXMj #AK_Step1_v12::#Bootcamp::Microbiology::32_Cardiorespiratory_Infections::03_Typical_Pneumonia_Pathogens #AK_Step1_v12::#FirstAid::03_Microbiology::02_Clinical_Bacteriology::19_Mycobacteria::*Mycobacterium_Tuberculosis #AK_Step1_v12::#AMBOSS::dnaoHO #AK_Step1_v12::#SketchyMicro::01_Bacteria::08_Mycobacteria::01_Mycobacterium_Tuberculosis #AK_Step2_v12::#AMBOSS::gw0FRR #AK_Step1_v12::^Other::^HighYield::1-HighYield #PANCE::PULM::infectious_disorders #AK_Step1_v12::#Bootcamp::Microbiology::35_Opportunistic_Infections::02_HPV_Carcinoma,_Reactivation_Tuberculosis,_Burkitt_Lymphoma #AK_Step1_v12::#UWorld::COMLEX::23853 #AK_Step2_v12::#Resources_by_rotation::IM::ome::rheum::ra #AK_Step2_v12::#B&B::08_Infectious_Disease::04_Other::04_Tuberculosis #AK_Step1_v12::#Bootcamp::Pathology::01_Inflammatory_Response::04_Chronic_Inflammatory_Response #AK_Step1_v12::#AMBOSS::fUakcP #AK_Original_Decks::Step_1::Lolnotacop::Bugs #AK_Step2_v12::#SketchyIM::07_Rheumatology::Retired_Lessons::02_Systemic_Rheumatic_Diseases::01_Rheumatoid_Arthritis_SOAP_[OLD_VERSION] #AK_Step1_v12::#USMLERx::2706.18 #AK_Step1_v12::#FirstAid::03_Microbiology::02_Clinical_Bacteriology::20_Tuberculosis #AK_Step1_v12::#OME::PreClinical::03_Immune::01_Immunology::16_Immunosuppression #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::12_TNF_Inhibitors_((Infliximab/Adalimumab/Certolizumab/Golimumab) #AK_Step1_v12::#B&B::16_Pathology::01_General::08_Granulomatous_Inflammation #AK_Step1_v12::#UWorld::Step::741 #AK_Step2_v12::#OME::01_Medicine::08_Rheumatology::03_Rheumatoid_Arthritis #AK_Step1_v12::#OME::03_Immune::01_Immunology::16_Immunosuppression #AK_Step1_v12::#AMBOSS::gNaF0O #AK_Step1_v12::#Physeo::02_Anatomy::02_Pulmonology::01_Overview_of_Respiratory_Anatomy !AK_UpdateTags::Step1decks::Lolnotacop::Bugs #AK_Step3_v12::#UWorld::6199 #AK_Step1_v12::#Physeo::06_Micro::02_Bacteria::41_Mycobacterium_Tuberculosis #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::09_TNF-alpha_Inhibitors #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::01_Autoimmune_disease_therapy::*Infliximab #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies #AK_Step1_v12::#Bootcamp::Microbiology::08_Mycobacteria::02_Pulmonary_Tuberculosis_Pathophysiology !AK_UpdateTags::AnKing_Image::Aiman #AK_Step2_v12::Original_decks::Dorian::im::ome::rheum::ra #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::03_Anti-inflammatory::04_TNF_Inhibitors #AK_Step1_v12::#Pixorize::04_Microbiology::06_Bacteria-Gram_Indeterminate::01_Mycobacterium_tuberculosis:_Overview #AK_Step1_v12::#Pixorize::02_Immunology::05_Cytokines::01_TNF-alpha #AK_Step1_v12::#Bootcamp::Musculoskeletal::15_Pharmacology::07_TNF_Alpha_Inhibitors_And_Monoclonal_Antibodies